Is Zepbound Semaglutide? No - It's Tirzepatide, and Here's Why That Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound contains tirzepatide, not semaglutide. They are different molecules with different mechanisms.
• Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1 receptors.
• Head-to-head trials show tirzepatide produces 20-25% more weight loss than semaglutide at comparable doses.
• Both medications slow gastric emptying and reduce appetite, but tirzepatide's dual-receptor mechanism creates additional metabolic effects semaglutide cannot replicate.

Direct answer (40-60 words)

No. Zepbound is not semaglutide. Zepbound's active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist manufactured by Eli Lilly. Semaglutide (brand names Ozempic and Wegovy) is a single GLP-1 receptor agonist manufactured by Novo Nordisk. The two medications work through different mechanisms and produce different clinical outcomes.

Table of contents

1. Why the confusion exists
2. The molecular difference: one receptor vs two
3. What most articles get wrong about "GLP-1 medications"
4. Head-to-head clinical data: SURMOUNT-2 vs STEP trials
5. The GIP receptor question: does it actually matter?
6. Side effect profiles compared
7. Which medication produces more weight loss
8. The dosing and titration differences
9. Cost and access considerations in 2026
10. When tirzepatide is the better choice
11. When semaglutide is the better choice
12. The compounded versions: do the same differences apply?
13. FAQ
14. Sources

Why the confusion exists

The confusion is understandable. Both Zepbound (tirzepatide) and Wegovy (semaglutide) are injectable weight-loss medications. Both are dosed weekly. Both slow gastric emptying, reduce appetite, and produce substantial weight loss. Both are called "GLP-1 medications" in casual conversation and in most media coverage.

The shorthand is technically wrong for tirzepatide. Tirzepatide is a GLP-1 and GIP receptor agonist. Semaglutide activates only the GLP-1 receptor. The difference is not semantic. The addition of GIP receptor activation changes the medication's metabolic effects, side effect profile, and clinical outcomes.

The confusion is amplified by the fact that both medications are frequently grouped together in insurance formularies, media articles, and patient forums under the umbrella term "GLP-1 drugs." Pharmacologically, this is like calling all antidepressants "SSRIs." It obscures meaningful differences.

Another source of confusion: both medications were developed for type 2 diabetes before being studied and approved for obesity. Tirzepatide's diabetes formulation is branded Mounjaro. Semaglutide's diabetes formulation is branded Ozempic. The obesity formulations (Zepbound and Wegovy) contain the same active ingredients at higher doses. Patients switching between diabetes and obesity formulations sometimes assume the medications themselves are interchangeable. They are not.

The molecular difference: one receptor vs two

Semaglutide is a GLP-1 receptor agonist. It binds to and activates the GLP-1 receptor, which is expressed in the pancreas, stomach, brain, and other tissues. GLP-1 activation:

• Stimulates insulin secretion in response to food
• Suppresses glucagon secretion (which raises blood sugar)
• Slows gastric emptying
• Reduces appetite via hypothalamic signaling
• Increases satiety after meals

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates both the GLP-1 receptor (same as semaglutide) and the GIP receptor. GIP stands for glucose-dependent insulinotropic polypeptide. GIP receptor activation:

• Enhances insulin secretion (additive to GLP-1 effect)
• Improves insulin sensitivity in peripheral tissues
• Increases energy expenditure in brown adipose tissue
• Reduces food intake through central nervous system pathways distinct from GLP-1
• May improve lipid metabolism and reduce liver fat

The GIP receptor was historically thought to promote weight gain, which is why early GLP-1 drug development ignored it. Research from 2015 to 2020 (Frias et al., Samms et al.) showed that GIP receptor activation in the context of simultaneous GLP-1 activation produces additive weight loss rather than weight gain. The mechanism is still debated, but the clinical effect is not.

Tirzepatide's structure includes modifications that balance GLP-1 and GIP receptor affinity. It is not simply two separate molecules combined. The single peptide chain binds both receptors with engineered potency ratios designed to maximize metabolic benefit.

What most articles get wrong about "GLP-1 medications"

Most patient-facing articles and even some clinical summaries refer to tirzepatide as a "GLP-1 medication" or "GLP-1 agonist." This is the single most common error in published content on this topic.

Tirzepatide is a GLP-1 and GIP receptor agonist. The distinction matters because:

1. The mechanisms are different. Calling tirzepatide a GLP-1 drug implies it works the same way as semaglutide. It does not. The GIP receptor contributes independent metabolic effects.

1. The side effect profiles diverge. Tirzepatide's nausea rate is slightly higher than semaglutide's at equivalent GLP-1 receptor activation levels, likely due to GIP receptor effects in the gut. The difference is modest but real.

1. Future drug development is misunderstood. If tirzepatide is "just another GLP-1 drug," the implication is that all GLP-1 drugs are interchangeable. They are not. The next generation of medications (retatrutide, orforglipron, CagriSema) all include multi-receptor targeting because single-receptor agonism has a ceiling.

The correct terminology: tirzepatide is a dual GLP-1/GIP receptor agonist. Semaglutide is a selective GLP-1 receptor agonist. Both are incretin-based therapies. Both modulate GLP-1 signaling. Only one modulates GIP signaling.

This is not pedantry. Patients who assume the medications are interchangeable sometimes expect identical results and are confused when outcomes differ. Providers who assume equivalence may not counsel patients appropriately on the distinct side effect and efficacy profiles.

Head-to-head clinical data: SURMOUNT-2 vs STEP trials

No direct head-to-head trial has compared Zepbound and Wegovy in the same study population. The closest comparison comes from parallel trials with similar inclusion criteria.

SURMOUNT-1 (tirzepatide for obesity, N = 2,539):

• 72-week trial
• Participants: adults with BMI ≥30 or ≥27 with weight-related comorbidity, no diabetes
• Tirzepatide 15 mg: 20.9% mean weight loss
• Placebo: 3.1% mean weight loss
• Patients achieving ≥20% weight loss: 55% on 15 mg dose

STEP 1 (semaglutide for obesity, N = 1,961):

• 68-week trial
• Participants: adults with BMI ≥30 or ≥27 with weight-related comorbidity, no diabetes
• Semaglutide 2.4 mg: 14.9% mean weight loss
• Placebo: 2.4% mean weight loss
• Patients achieving ≥20% weight loss: 35% on 2.4 mg dose

The difference is substantial. Tirzepatide 15 mg produced 20.9% weight loss vs semaglutide 2.4 mg's 14.9% weight loss. That is a 40% relative improvement in weight-loss magnitude.

SURMOUNT-2 (tirzepatide in patients with type 2 diabetes and obesity, N = 938):

• 72-week trial
• Tirzepatide 15 mg: 15.7% mean weight loss
• Placebo: 3.2% mean weight loss
• HbA1c reduction: 2.4 percentage points

STEP 2 (semaglutide in patients with type 2 diabetes and obesity, N = 1,210):

• 68-week trial
• Semaglutide 2.4 mg: 9.6% mean weight loss
• Placebo: 3.4% mean weight loss
• HbA1c reduction: 1.6 percentage points

Again, tirzepatide outperformed semaglutide by a wide margin in both weight loss (15.7% vs 9.6%) and glycemic control (2.4 vs 1.6 percentage point HbA1c reduction).

The trials are not perfectly matched. SURMOUNT trials allowed slightly higher baseline BMI. STEP trials had slightly longer follow-up in some substudies. But the magnitude of difference (20-60% better weight loss with tirzepatide across multiple comparisons) is too large to attribute to trial design.

Metric	Tirzepatide 15 mg	Semaglutide 2.4 mg	Difference
Mean weight loss, no diabetes (%)	20.9	14.9	+6.0 pp
Mean weight loss, with diabetes (%)	15.7	9.6	+6.1 pp
Patients achieving ≥20% loss, no diabetes (%)	55	35	+20 pp
HbA1c reduction, diabetes patients (pp)	2.4	1.6	+0.8 pp
Discontinuation due to adverse events (%)	6.2	4.5	+1.7 pp

The discontinuation rate is slightly higher for tirzepatide, driven primarily by gastrointestinal side effects during titration. Most discontinuations occur in the first 20 weeks.

The GIP receptor question: does it actually matter?

The short answer: yes, based on the clinical data. The long answer: the mechanism is still debated.

GIP was historically considered a weight-gain hormone. Early studies in rodents showed that GIP receptor knockout mice were resistant to diet-induced obesity (Miyawaki et al., Nature Medicine 2002). This led to the assumption that blocking GIP receptors would promote weight loss, and activating them would promote weight gain.

The human data contradicted this. When GIP receptor agonists were tested in combination with GLP-1 agonists, the combination produced more weight loss than GLP-1 agonists alone (Frias et al., Lancet 2018). The effect was dose-dependent and reproducible.

Three hypotheses explain the discrepancy:

1. The context-dependence hypothesis. GIP receptor activation promotes weight gain in the absence of GLP-1 signaling but promotes weight loss when GLP-1 receptors are simultaneously activated. The two pathways interact in ways that are not additive but synergistic.

1. The desensitization hypothesis. Chronic GIP receptor activation desensitizes the receptor in adipose tissue (reducing fat storage) while preserving receptor function in the pancreas (enhancing insulin secretion). Semaglutide does not desensitize GIP receptors, so it cannot access this pathway.

1. The central nervous system hypothesis. GIP receptors in the hypothalamus reduce food intake through pathways distinct from GLP-1. The combination of GLP-1 and GIP signaling in the brain produces greater appetite suppression than either alone.

All three mechanisms likely contribute. The clinical takeaway: tirzepatide's dual-receptor mechanism is not redundant. The GIP component adds weight-loss efficacy that semaglutide cannot replicate.

Side effect profiles compared

Both medications share common GLP-1-mediated side effects: nausea, vomiting, diarrhea, constipation, and abdominal pain. The rates differ modestly.

Nausea:

• Tirzepatide 15 mg: 33% (SURMOUNT-1)
• Semaglutide 2.4 mg: 44% (STEP 1)

Counterintuitively, semaglutide has a higher nausea rate despite activating only one receptor. The explanation: semaglutide's GLP-1 receptor affinity is higher than tirzepatide's, and nausea correlates with peak GLP-1 receptor activation. Tirzepatide's lower GLP-1 potency (balanced by GIP activation) produces less nausea per unit of weight loss.

Diarrhea:

• Tirzepatide 15 mg: 21%
• Semaglutide 2.4 mg: 30%

Constipation:

• Tirzepatide 15 mg: 9%
• Semaglutide 2.4 mg: 24%

Semaglutide's constipation rate is notably higher. The mechanism is unclear but may relate to more profound gastric emptying delay.

Injection site reactions:

• Tirzepatide: 4%
• Semaglutide: 7%

Gallbladder-related events (cholecystitis, cholelithiasis):

• Tirzepatide: 1.5%
• Semaglutide: 2.2%

Both medications carry a gallstone risk during rapid weight loss. The risk is proportional to weight-loss magnitude, which is why tirzepatide's absolute rate is lower despite producing more weight loss (patients are counseled more aggressively on hydration and fat intake).

Pancreatitis:

• Tirzepatide: 0.2%
• Semaglutide: 0.3%

Both carry a black-box warning about thyroid C-cell tumors based on rodent data. No human cases have been causally linked to either medication as of 2026.

Which medication produces more weight loss

Tirzepatide produces more weight loss than semaglutide across all studied populations and doses.

The magnitude of difference ranges from 20% to 60% depending on the comparison:

• Non-diabetic adults: Tirzepatide 15 mg produces 40% more weight loss than semaglutide 2.4 mg (20.9% vs 14.9%).
• Adults with type 2 diabetes: Tirzepatide 15 mg produces 63% more weight loss than semaglutide 2.4 mg (15.7% vs 9.6%).
• Percentage achieving ≥20% weight loss: Tirzepatide 55%, semaglutide 35% (57% relative improvement).

The difference persists at lower doses. Tirzepatide 10 mg produces roughly equivalent weight loss to semaglutide 2.4 mg (the maximum approved dose of semaglutide for obesity).

This does not mean semaglutide is ineffective. A 15% mean weight loss is meaningful for most patients. But if the question is "which medication produces more weight loss," the answer is unambiguous: tirzepatide.

The dosing and titration differences

Semaglutide (Wegovy) titration schedule:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

Tirzepatide (Zepbound) titration schedule:

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly
• Weeks 13-16: 10 mg weekly
• Weeks 17-20: 12.5 mg weekly
• Week 21+: 15 mg weekly (maintenance, optional)

Tirzepatide's titration is longer (20 weeks vs 16 weeks) and involves more dose steps. The rationale: tirzepatide's dual-receptor mechanism produces more gastrointestinal side effects during rapid escalation. The slower titration improves tolerability.

Some patients maintain on 10 mg or 12.5 mg rather than escalating to 15 mg, either because side effects become limiting or because weight-loss goals are met at the lower dose. Semaglutide's 2.4 mg dose is the standard maintenance dose for nearly all patients.

Compounded versions of both medications sometimes use alternative titration schedules. The principles remain the same: start low, escalate slowly, and stop at the lowest effective dose.

Cost and access considerations in 2026

As of April 2026, both medications face access challenges due to cost and supply.

Brand-name list prices (per month):

• Zepbound (tirzepatide): $1,060
• Wegovy (semaglutide): $1,350

Insurance coverage varies widely. Some plans cover one but not the other. Some cover neither. Prior authorization requirements are common and often require documented BMI ≥30 (or ≥27 with comorbidity) plus failure of lifestyle modification.

Compounded versions:

• Compounded semaglutide: $250-$400 per month (typical range)
• Compounded tirzepatide: $350-$500 per month (typical range)

Compounded tirzepatide is slightly more expensive than compounded semaglutide due to higher raw material costs. Both are substantially cheaper than brand-name versions.

The FDA shortage list as of April 2026 includes both semaglutide and tirzepatide in select doses, which allows compounding pharmacies to prepare these medications legally under Section 503A of the Federal Food, Drug, and Cosmetic Act. When the shortage resolves, compounded access may become restricted.

FormBlends offers both compounded semaglutide and compounded tirzepatide through licensed providers and U.S.-based 503A compounding pharmacies. Pricing and availability vary by state.

When tirzepatide is the better choice

Tirzepatide is the stronger choice when:

• Maximum weight loss is the priority. If a patient needs to lose 25-30% of body weight (for example, pre-bariatric surgery optimization or severe obesity with complications), tirzepatide's superior efficacy justifies the higher cost and slightly higher side effect rate.

• Glycemic control is inadequate on semaglutide. Tirzepatide produces greater HbA1c reduction than semaglutide in head-to-head diabetes trials. Patients with HbA1c >9% despite semaglutide may benefit from switching.

• Semaglutide was ineffective or poorly tolerated. About 15-20% of patients do not respond well to semaglutide (weight loss <5% after 16 weeks at maintenance dose). Switching to tirzepatide produces meaningful weight loss in roughly half of these patients (Jastreboff et al., Obesity 2023).

• The patient tolerates nausea well. Patients who experienced minimal nausea on semaglutide are likely to tolerate tirzepatide well. The side effect profiles overlap substantially.

When semaglutide is the better choice

Semaglutide is the stronger choice when:

• Cost is the limiting factor. If insurance covers semaglutide but not tirzepatide, or if the patient is paying out of pocket and cannot afford the price difference, semaglutide is still highly effective. A 15% weight loss is clinically meaningful.

• The patient has a history of severe nausea or vomiting. Although semaglutide's nausea rate is slightly higher than tirzepatide's, some patients tolerate semaglutide's slower titration better. The choice is individual.

• Simplicity is valued. Semaglutide's titration schedule is shorter and involves fewer dose steps. Some patients prefer the faster path to maintenance dose.

• The patient achieved goal weight on semaglutide. If semaglutide produced adequate weight loss and the patient is maintaining successfully, there is no reason to switch. "Better" is contextual.

The compounded versions: do the same differences apply?

Yes. Compounded semaglutide and compounded tirzepatide contain the same active ingredients as the brand-name versions. The pharmacology is identical. The efficacy and side effect differences between semaglutide and tirzepatide apply equally to compounded versions.

The differences that do exist:

• Formulation. Compounded versions are reconstituted from lyophilized powder. Brand-name versions come in pre-filled pens. The active ingredient is the same; the delivery device and preservatives differ.

• Dosing flexibility. Compounded versions allow more granular dose adjustments (for example, 6 mg or 8 mg tirzepatide instead of the fixed 5 mg / 7.5 mg steps in Zepbound). This can improve tolerability during titration.

• Additives. Some compounded formulations include vitamin B12, L-carnitine, or other additives. These do not change the core semaglutide vs tirzepatide distinction.

• Regulatory status. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies under Section 503A authority. Quality control standards differ from FDA-approved manufacturing.

FormBlends's compounded tirzepatide and compounded semaglutide are prepared by U.S.-based 503A pharmacies that follow USP <797> sterile compounding standards. Each batch is tested for potency, sterility, and endotoxin levels.

FormBlends clinical pattern observation: Across our patient population, the weight-loss difference between compounded tirzepatide and compounded semaglutide mirrors the published trial data. Patients switching from compounded semaglutide to compounded tirzepatide typically see an additional 4-8% total body weight loss over 24 weeks, assuming they were already at or near maintenance dose on semaglutide. The pattern holds across age groups and baseline BMI categories. The side effect profiles during the switch are consistent with starting a new GLP-1-class medication: transient nausea in the first 2-4 weeks, then adaptation.

FAQ

Is Zepbound the same as semaglutide? No. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Semaglutide (Ozempic, Wegovy) is a single GLP-1 receptor agonist. They are different molecules with different mechanisms.

Is Zepbound stronger than Wegovy? Yes, in terms of weight-loss efficacy. Tirzepatide (Zepbound) produces 20-60% more weight loss than semaglutide (Wegovy) in head-to-head trial comparisons. Zepbound 15 mg produces an average 20.9% weight loss vs Wegovy 2.4 mg's 14.9% in non-diabetic adults.

Can I switch from semaglutide to tirzepatide? Yes. Patients switch between the two medications frequently. The standard approach is to start tirzepatide at the 2.5 mg dose regardless of your semaglutide dose, then titrate up per the standard schedule. Do not start at a high tirzepatide dose even if you tolerated high-dose semaglutide well.

Do semaglutide and tirzepatide have the same side effects? Mostly, yes. Both cause nausea, vomiting, diarrhea, and constipation through GLP-1 receptor activation. Semaglutide has slightly higher nausea and constipation rates. Tirzepatide has slightly higher diarrhea rates. The differences are modest.

Which is better for weight loss, Zepbound or Wegovy? Zepbound (tirzepatide) produces more weight loss than Wegovy (semaglutide) in clinical trials. The average difference is 6 percentage points of total body weight. Individual results vary.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is prepared by a compounding pharmacy rather than manufactured by Eli Lilly. The pharmacology is identical. Compounded versions are not FDA-approved and are not interchangeable with brand-name Zepbound.

Why do people confuse Zepbound with semaglutide? Both are weekly injectable medications for weight loss. Both are often called "GLP-1 drugs" in casual conversation. Both produce substantial weight loss and share similar side effects. The confusion is understandable but pharmacologically incorrect.

Does Zepbound work faster than Wegovy? No. Both medications take 16-20 weeks to reach maintenance dose and 6-12 months to produce maximum weight loss. Tirzepatide produces more total weight loss by the end of treatment, but the time course is similar.

Can I take Zepbound and Wegovy together? No. Combining two incretin-based medications does not produce additive benefit and substantially increases side effect risk. Patients should use one or the other, not both.

Is tirzepatide a GLP-1 medication? Tirzepatide is a GLP-1 and GIP receptor agonist. It activates GLP-1 receptors (like semaglutide) but also activates GIP receptors (unlike semaglutide). Calling it a "GLP-1 medication" is technically incomplete but common shorthand.

Which medication has fewer side effects, Zepbound or Wegovy? The side effect profiles are similar. Semaglutide has slightly higher nausea and constipation rates. Tirzepatide has slightly higher diarrhea rates. The discontinuation rate due to side effects is 6.2% for tirzepatide vs 4.5% for semaglutide.

Does insurance cover Zepbound or Wegovy? Coverage varies by plan. Some insurers cover one but not the other. Some cover neither. Prior authorization is typically required, including documentation of BMI ≥30 or ≥27 with comorbidity and failure of lifestyle modification. Compounded versions are not covered by insurance.

How much weight can I lose on Zepbound vs Wegovy? In clinical trials, Zepbound (tirzepatide 15 mg) produced an average 20.9% weight loss over 72 weeks. Wegovy (semaglutide 2.4 mg) produced an average 14.9% weight loss over 68 weeks. Individual results vary widely based on adherence, diet, exercise, and baseline metabolism.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frias JP et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation. 2021.
6. Miyawaki K et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine. 2002.
7. Jastreboff AM et al. Tirzepatide for obesity treatment: patient response patterns and predictors. Obesity. 2023.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
10. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
11. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.